Main menu

Using nanopore sequencing for mRNA vaccine quality control: a journey from R&D to GMP


Abstract The production of mRNA vaccines involves costly and time-intensive quality testing. Contaminants, including double-stranded, degraded, or off-target mRNAs, can undermine the efficacy and safety of the vaccine and may emerge at any stage of the mRNA manufacturing process. We describe the development and validation of an Oxford Nanopore sequencing pipeline, designed for quality control of mRNA vaccines throughout their manufacture. Our pipeline streamlines the assessment of mRNA sequence identity, purity, and integrity from the 5’ cap to the poly(A) tail. To adapt this analytical pipeline for clinical-grade mRNAs, we also describe the development of mRNA standards, suitable for the qualification and validation of quality control equipment and analytical methods. Our results demonstrate that Oxford Nanopore sequencing delivers comprehensive mRNA quality control information, thereby supporting routine mRNA vaccine manufacturing and facilitating continuous process improvements.  Biography Helen Gunter is a Senior Research Scientist at the BASE Facility, University of Queensland. Her research focuses on advancing tools to enhance the design, quality, and efficacy of mRNA vaccines.

Authors: Helen Gunter

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag